Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

MCP-1

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Inflammation
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

Meta-analysis Results: Levels of MCP-1, a chemokine also known as C-C motif chemokine 2, appeared slightly elevated in the cerebrospinal fluid of people with Alzheimer’s disease and controls (effect size = 1.123). The effect was significant (p < 0.0001); however, the meta-analysis was limited to three eligible comparisons. This effect was not found in plasma and serum levels (no consistent difference in the plasma and serum of people with Alzheimer’s disease and in controls (effect size = 0.999, p = 0.98639).

What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physician who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Data collected by multiple groups. Alzforum meta analysis.

  1. “Alzheimer's Disease vs Control: MCP-1 (CSF).”Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-mcp-1-csf

  2. “Alzheimer's Disease vs Control: MCP-1 (Plasma and Serum).” Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-mcp-1-plasma-and-serum

  3. Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009). Monocyte chemoattractant protein-1 (MCP-1): an overview. Journal of interferon & cytokine research, 29(6), 313-326. https://www.ncbi.nlm.nih.gov/pubmed/19441883

  4. Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., ... & Scarpini, E. (2006). Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiology of Aging, 27(12), 1763-1768. https://www.ncbi.nlm.nih.gov/pubmed/16307829

  5. Zhang, R., Miller, R. G., Madison, C., Jin, X., Honrada, R., Harris, W., ... & McGrath, M. S. (2013). Systemic immune system alterations in early stages of Alzheimer's disease. Journal of Neuroimmunology, 256(1-2), 38-42. https://www.ncbi.nlm.nih.gov/pubmed/23380586